Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Update

Mustang Bio, Inc. (NASDAQ:MBIO) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 150,627 shares, an increase of 176.0% from the May 31st total of 54,570 shares. Based on an average trading volume of 553,998 shares, the short-interest ratio is presently 0.3 days. Currently, 2.1% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mustang Bio in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Mustang Bio Stock Performance

NASDAQ MBIO traded up $0.03 on Friday, hitting $0.70. 44,430 shares of the stock were exchanged, compared to its average volume of 328,348. The stock has a fifty day moving average price of $0.70 and a two-hundred day moving average price of $0.86. The firm has a market capitalization of $5.33 million, a P/E ratio of -1.47 and a beta of 2.08. Mustang Bio has a 52-week low of $0.53 and a 52-week high of $7.00.

Mustang Bio (NASDAQ:MBIO) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($140.00) by $139.86.

Institutional Trading of Mustang Bio

An institutional investor recently raised its position in Mustang Bio stock. Kestra Advisory Services LLC grew its holdings in shares of Mustang Bio, Inc. (NASDAQ:MBIO) by 68.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 111,042 shares of the company’s stock after buying an additional 44,934 shares during the quarter. Kestra Advisory Services LLC owned 1.52% of Mustang Bio worth $109,000 at the end of the most recent reporting period. 9.95% of the stock is owned by hedge funds and other institutional investors.

About Mustang Bio

Mustang Bio, Inc is a clinical?stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T?cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral?based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.